TABLE 1

Comparison of the clinical features of the three sputum transcriptome-associated clusters (TACs)

TAC1TAC2TAC3p-value#
TAC1 versus TAC2TAC1 versus TAC3TAC2 versus TAC3
Subjects302252
Age years56.5±11.349.6±13.649.1±13.80.0590.0110.907
Age of onset years35.0±19.217.3±16.223.5±19.57.3×10−40.0120.163
Female17 (56.7)15 (68.2)28 (53.8)0.5790.9870.376
BMI kg·m–227.3±5.028.5±5.427.8±5.40.3960.6460.606
Smoker7 (23.3)3 (13.6)13 (25.0)0.6031.0000.437
Nasal polyps14 (46.7)6 (27.3)14 (26.9)0.2580.1151.000
Allergic rhinitis12 (40.0)10 (45.5)20 (38.5)0.9131.0000.763
Eczema7 (23.3)13 (59.1)13 (25.0)0.0201.0000.110
Severe asthma29 (96.7)18 (81.8)37 (71.2)0.1870.0120.503
Oral corticosteroid use17 (56.7)8 (36.4)13 (25.0)0.2430.0090.478
Atopy21 (70.0)14 (63.6)38 (73.1)0.8540.9650.593
Exacerbations year–12.0 (1.0–3.0)1.0 (1.0–2.8)1.0 (0.0–2.0)0.1440.0120.328
FEV1 % pred55.1 (41.9–74.1)62.9 (47.1–83.5)74.2 (63.7–89.8)0.3033.1×10−40.025
Total IgE IU·mL−1152.0 (70.5–272.2)90.5 (31.3–187.5)89.4 (43.0–170.0)0.2410.0910.852
Blood leukocytes ×103 μL−19.04 (7.07–10.82)7.60 (6.15–9.87)6.81 (6.00–8.45)0.2660.0060.248
Blood eosinophils ×103 μL−10.43 (0.25–0.58)0.25 (0.10–0.40)0.20 (0.12–0.30)0.0133.9×10−40.532
Blood neutrophils ×103 μL−15.12 (3.89–7.41)4.46 (3.90–6.48)4.01 (3.32–4.90)0.6130.0160.111
Sputum eosinophils %30.9 (15.0–51.4)0.6 (0.2–2.4)1.0 (0.2–4.5)3.2×10−89.2×10−110.593
Sputum neutrophils %49.0 (25.9–70.5)90.9 (84.9–94.4)48.8 (33.3–63.5)7.4×10−80.7843.4×10−10
Sputum eosinophils >10%25 (83.3)06 (11.5)1.5×10−84.9×10−100.232
FeNO ppb29.5 (20.0–57.5)22.0 (14.0–26.0)27.5 (18.1–42.4)0.0900.4210.110
Serum periostin ng·mL−160.2 (50.2–72.4)49.9 (43.2–52.9)42.6 (37.0–53.2)0.0518.8×10−40.076
CRP mg·L−12.5 (1.0–3.6)5.4 (3.0–7.2)1.9 (1.0–5.0)0.0220.7560.010
  • Data are presented as n, mean±sd, n (%) or median (interquartile range), unless otherwise stated. BMI: body mass index; FEV1: forced expiratory volume in 1 s; FeNO: exhaled nitric oxide fraction; CRP: C-reactive protein. #: Kruskal–Wallis or ANOVA test.